Objectives: Treatment of HIV-infected patients is associated with early onset of aging-related comorbidities. Some of the adverse effects of antiretroviral therapy have been attributed to the mitochondrial toxicity of nucleoside reverse transcriptase inhibitors (NRTI), and it is of note that mitochondrial dysfunction and oxidative stress are involved in the aging processes. In this regard, we examined whether NRTIs could accelerate the senescence of cultured cells.

Methods: Human fibroblasts were exposed to NRTIs from culture passages 1 to 14. Cytochrome c-oxidase (COX) subunits 2 and 4, mitochondrial potential and mass, and reactive oxygen species (ROS) were quantified at each passage. Proliferation, cell-cycle arrest, senescence-associated β-galactosidase activity, and morphology were assessed in parallel. Mitochondrial and senescence markers were assessed in cultured murine preadipocytes and in fat samples from lipodystrophic HIV-infected patients.

Results: Stavudine and zidovudine induced mitochondrial dysfunction and increased ROS levels in fibroblasts at early culture passages, while cell division gradually slowed. At passages 8–12, fibroblasts exposed to stavudine or zidovudine but not abacavir, didanosine, lamivudine and tenofovir were senescent, on the basis of p16INK4 and p21WAF–1 protein expression, cell morphology and senescence-associated-β-galactosidase activity. Senescence markers and COX2 underexpression were also found in 3T3-F442A preadipocytes exposed for 7 weeks to stavudine or zidovudine, but not lamivudine, and in adipose tissue samples from lipodystrophic HIV-infected patients on antiretroviral regimens containing stavudine or zidovudine.

Conclusions: Mitochondrial changes and oxidative damage could partly explain the premature senescence of fibroblasts and adipose cells induced by stavudine and zidovudine. This suggests that thymidine analogues might be involved in the early aging-related diseases observed in some HIV-infected patients taking antiretroviral drugs.

Introduction

Some antiretroviral drugs have significant mitochondrial toxicity [1–7]. This toxicity has been linked to a wide range of severe adverse events, including lipodystrophy. Lipodystrophy becomes apparent in the medium to long term and is mainly attributed to nucleoside reverse transcriptase inhibitors (NRTI) [1,3,4,6,8–10], especially the thymidine analogues stavudine and zidovudine [8,11–13]. The mitochondrial toxicity of NRTIs has been observed in cultured cell lines [12,14,15] and in fat tissue from lipodystrophic HIV-infected patients [11,16–21]. HIV-infected patients on antiretroviral treatment are also at an increased risk of aging-related complications such as neurodegeneration, osteopenia, atherosclerosis and diabetes [22,23]. Finally, oxidant stress, probably resulting from mitochondrial dysfunction, is increased in HIV-infected patients during antiretroviral treatment [24,25].

Cellular senescence results from a signal transduction program that leads to irreversible cell growth arrest and to a distinct set of phenotypic changes [26,27]. Abundant evidence implicates mitochondria in the aging process [27–30], and experimental data show a relationship between respiratory chain dysfunction, oxidative damage and aging in most model organisms. The free-radical theory of aging postulates that intracellular reactive oxygen species (ROS) production is a major determinant
of life span. Mitochondria are the main intracellular site of oxygen reduction and, hence, the site with the greatest potential for ROS formation and sensitivity to ROS toxicity. ROS can also form in the cytosol and in peroxisomes, as by-products of specific oxidases [31].

Human skin fibroblasts offer a good model for studying the cellular aging process in vitro [32]. Fibroblasts proliferate readily in primary culture but have limited proliferative potential, ultimately entering a state of replicative senescence. Senescent fibroblasts show irreversible growth arrest but remain viable for long periods. They are characterized by their distinct morphology, expression of senescence-associated β-galactosidase (SA-β-galactosidase) activity [33], and upregulation of cell-cycle checkpoint inhibitors such as p16INK4a and p21WAF1 [34,35].

In this study we investigated whether a series of NRTIs could induce mitochondrial dysfunction, oxidative stress and premature senescence in vitro, in human skin fibroblasts and murine preadipocytes exposed to the drugs during several culture passages. We also searched for mitochondrial alteration and senescence markers in adipose tissue samples from lipodystrophic HIV-infected patients taking NRTIs.

Methods

Cell culture, fat tissue samples and treatment

Primary cultures of fibroblasts originated from subcutaneous abdominal skin of two non-obese, healthy women aged 20 and 33 years obtained during plastic surgery. They were grown in DMEM medium (Gibco® Cell Culture, Invitrogen Corporation, San Diego, CA, USA) containing 1 g/l glucose, 20 mM l-glutamine, 25 mM Hepes, 110 mg/ml sodium pyruvate, 10% fetal bovine serum (FBS, Gibco® Cell Culture), 100 U/ml penicillin and 0.1 mg/ml streptomycin (Gibco® Cell Culture) and antibiotics [36]. Fibroblasts (passage 1) and adipose tissue from four HIV-infected patients aged 41–67 years who were on NRTI-based antiretroviral regimens that included stavudine or zidovudine (but not protease inhibitors), and from four HIV-seronegative, non-diabetic, 40 to 60 year-old controls, as described elsewhere [16]. We have previously reported altered cellular morphology and mitochondrial dysfunction in fat tissue from these same HIV-infected patients [20,38]. All the patients gave their informed consent for these studies.

Western blot analysis

Cell extracts prepared as previously described [36] were subjected to SDS–PAGE, blotted onto nitrocellulose membranes and probed with antibodies against p16INK4a and p21WAF1 (ref 554070 and 556431, BD-Pharmlingen, BD Biosciences, San Jose, CA, USA), the mitochondrial (mt) DNA-encoded subunit II (COX2) and the nuclear (n) DNA-encoded subunit IV (COX4) of cytochrome oxidase complex IV (ref A-6404 and A-21348, Molecular Probes, Eugene, OR, USA) and against porin (VDAC-1, ref PC548, Calbiochem, Merck Biosciences, Darmstadt, Germany). β-Actin (A-5441, Sigma Aldrich) was immunoprobed as an index of the cellular protein loading. The antibodies were detected with a chemiluminescence detection kit (GE Healthcare, Saclay, France). Gel quantification was performed with the ChemiGenius2 image analyser and software (Ozyme, St Quentin en Yvelines, France).

Mitochondrial membrane potential and mass

We used the cationic dye JC-1 (5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethyl-benzimidazo-carbocyanine iodide, T-3168, Molecular Probes) to evaluate mitochondrial membrane potential, and the MitoTracker Red 580 probe (MTR, M-22425, Molecular Probes) to measure mitochondrial mass [14]. Cellular content was estimated by the fluorescence of DNA using Hoechst 33258. Cells were cultured in 96-well plates, washed and incubated with JC-1 (4 μg/ml), MTR (50 nM) or Hoechst 33258 (0.01 μg/ml) in DMEM without FBS for 20 min at 37°C in the dark. Quantification was performed on a plate fluorescence reader (Spectrafluor Plus, Tecan-France, Trappes, France) at 595 and 530 nm (JC-1 aggregates and monomers, respectively), 630 nm (MTR) and 460 nm (Hoechst 33258). JC-1 and MTR in situ labelling was also examined by fluorescence microscopy.

ROS production

We used the CM-H2DCFDA derivatives (5′- and 6-chloromethyl-2′,7′-dichlorodihydrofluorescein...
diacetate, acetyl ester, C6827, Molecular Probes) as cell-permeant indicators of ROS. Cells were cultured in 96-well plates, washed and incubated with CM-H2DCFDA (9 μM) in DMEM without FBS for 20 min at 37°C in the dark. Fluorescence was quantified on a plate reader at 520 and 460 nm, respectively. Oxidized CM-H2DCFDA in situ localization was also examined by fluorescence microscopy.

ROS production was also detected by measuring the reduction of nitroblue tetrazolium (NBT, Sigma-Aldrich). Cells were incubated in medium containing 0.2% NBT for 90 min. Dark blue reduced NBT, dissolved in DMSO, was measured at 560 nm in a spectrophotometer.

### Population doubling level

The population doubling level (PDL) was calculated as previously described [39] as log₂(D/D₀), where D₀ and D are the numbers of cells at seeding and harvesting, respectively. Senescence was considered complete when cells were unable to complete one PDL during a 4-week period, including three consecutive weeks of refeeding with fresh complete medium. Control fibroblasts and 3T3-F442A preadipocytes did not reach replicative senescence at passages 18 and 15, respectively. The cumulative population doubling level (CPDL) was determined by adding the PDL values measured at each culture passage.

### Cellular BrdU labelling

Dividing cells were identified by measuring bromodeoxyuridine (BrdU) incorporation according to the manufacturer’s instructions (BrdU in situ detection kit, BD Biosciences Pharmingen, San Diego, CA, USA). Briefly, half-confluent cells were incubated for 16 h with BrdU (15 μM), then fixed and permeabilized. Anti-BrdU antibodies, streptavidine-horse radish peroxidase and the diaminobenzidine (DAB) substrate were then added successively for 60, 30 and 5 min. Dividing cells (red-brown), examined by phase contrast microscopy at 20× magnification, were counted in four randomly selected fields and expressed as a percentage of total cells.

### Senescence-associated β-galactosidase assay

β-Galactosidase activity at pH 6 has been widely used as a biomarker of cellular senescence in vivo and in vitro [33]. Cells on cover slips were fixed for 3–5 min at 22°C with 2% formaldehyde/0.2% glutaraldehyde and incubated overnight at 37°C in 1 mg/ml 5-bromo-4-chloro-3-indolyl-β-D-galactoside (X-gal), 40 mM citric acid-sodium phosphate (pH 6 or 4), 5 mM potassium ferricyanide, 5 mM potassium ferrocyanide, 150 mM NaCl and 2 mM MgCl₂. The blue X-gal-stained cells observed at pH 6 and pH 4 were examined by phase contrast microscopy (20× magnification) and counted in eight fields (500 cells).

The ratio of pH 6- to pH 4-positive blue cells, which specifically represents SA-β-galactosidase activity, was calculated.

### Results

#### Some NRTIs induce mitochondrial dysfunction in cultured fibroblasts

Stavudine and zidovudine, two NRTIs previously shown to induce mitochondrial toxicity in adipocytes [6,11,14,15], also altered mitochondrial function in cultured fibroblasts (Figure 1). They reduced the mitochondrial membrane potential, as shown by the JC-1 aggregate/monomer ratio, which was decreased by 35–50% at early (3–4) and late (9–13) passages (Figure 1A, left), as compared with untreated cells. Abacavir, didanosine, lamivudine and tenofovir did not induce mitochondrial depolarization at passages 7–8 (Figure 1A, right), and all along the culture passages up to passage 13 (not shown). Further indication of the specificity of the JC-1 assay was supported by fluorescence microscopy. Indeed, in untreated fibroblasts, JC-1 red-orange fluorescence is mainly localized in the cytoplasm in rod-like structures that are typical of mitochondria (data not shown).

Stavudine and zidovudine, but not other NRTIs, markedly reduced the protein expression of COX2, a mtDNA-encoded subunit of cytochrome oxidase complex IV of the respiratory chain, and increased expression of the nDNA-encoded COX4 subunit of the same complex. The expression of the nDNA-encoded mitochondrial VDAC-1 (porin) was also increased (Figure 1B, left). Densitometric quantification indicated that stavudine and zidovudine reduced the ratio COX2/COX4 by 3.1-fold and 4.9-fold, respectively (Figure 1B, right), and all along the culture passages up to passage 35–50% at early (3–4) and late (9–13) passages (Figure 1A, left), as compared with untreated cells. Abacavir, didanosine, lamivudine and tenofovir did not induce mitochondrial depolarization at passages 7–8 (Figure 1A, right), and all along the culture passages up to passage 13 (not shown). Further indication of the specificity of the JC-1 assay was supported by fluorescence microscopy. Indeed, in untreated fibroblasts, JC-1 red-orange fluorescence is mainly localized in the cytoplasm in rod-like structures that are typical of mitochondria (data not shown).

MTR dye fluorescence indicated that stavudine and zidovudine increased mitochondrial proliferation in response to
medium- or long-term incubation with stavudine or zidovudine was confirmed by in situ fluorescence microscopy, assessed at passage 8 (Figure 1C, right).

Stavudine and zidovudine increase ROS production

ROS production was evaluated indirectly by measuring the oxidation status of the permeant derivatives CM-H$_2$DCFDA and the reduction of NBT. In fibroblasts exposed to stavudine or zidovudine (Figure 2A) CM-H$_2$DCFDA oxidation increased in two stages, with a 2.5- to threefold rise at passages 3 to 6 followed by a further increase at passages 7–9 (five- to eightfold higher than the control value). Incubation of cells with abacavir, lamivudine, didanosine or tenofovir did not increase ROS production at any passage (Figure 2A, top).

**Figure 1.** NRTIs induce mitochondrial dysfunction in human fibroblasts

Fibroblasts were cultured from passages 1 to 13 in 96-well plates in the presence or absence of the indicated nucleoside reverse transcriptase inhibitor (NRTI; see colour code). (A) Cells were incubated for 30 min with JC-1 at 37°C in the dark. Monomer green fluorescence was quantified on a fluorescence plate reader at 530 nm and aggregate red–orange fluorescence at 595 nm. The results are expressed as the ratio aggregate/monomer fluorescence at the indicated passages (left), and at passages 7–8 (right). Values are means ±SEM of three experiments performed in quadruplicate. (B) Western blots of fibroblast lysates (left) were revealed with antibodies against the mitochondrial proteins cytochrome c oxidase IV subunits 2 and 4 (COX2, COX4) and porin and against β-actin, as indicated. Representative blots (passages 5–6) from triplicate experiments are shown. The COX2/COX4 protein expression ratio was determined by densitometric scanning and expressed as a percentage of control (mean ±SEM) (right). (C) Mitochondrial mass was measured by MitoTracker Red (MTR) labelling at 630 nm and normalized to the cellular DNA content determined in parallel by Hoechst 33258 staining at 460 nm. MTR/DNA fluorescence was assessed at all passages (3–12; colour code as in A and B). The results are the means ±SEM at the indicated passages. Experiments were performed at least four times on quadruplicate samples (left). Living cells (passage 8) were stained in situ using MTR (red labelling) and examined by fluorescence microscopy. Scale bar represents 20 μm (right). *P<0.05 as compared with control cells.
confirmed the increased level of ROS in cells exposed to stavudine or zidovudine, as compared with controls. The green fluorescence of CM-H$_2$DCFDA was predominantly located near the nucleus. Irrelevant green fluorescence was observed in untreated cells and in cells exposed to abacavir, didanosine, lamivudine or tenofovir (Figure 2A and data not shown).

The gradual increase in ROS production induced by stavudine and zidovudine was also observed by measuring NBT reduction, which was significantly increased at all studied passages (3–13) as compared with control cells and cells incubated with abacavir, lamivudine, didanosine or tenofovir (Figure 2B). At passages 7–8, didanosine significantly increased NBT reduction as compared with control cells. However, didanosine had no effect on NBT reduction at higher culture passages (9–13) and failed to increase significantly CM-H$_2$DCFDA oxidation at any culture passage (Figure 2A, top).

Fibroblasts incubated with stavudine or zidovudine also exhibited a striking decrease in their replicative capacity measured in terms of BrdU incorporation in half-confluent cells (60–80% reduction at passages 6–8), as compared with control cultures and in cultures exposed to abacavir, didanosine, lamivudine or tenofovir (Figure 3B, top). Interestingly, most fibroblasts incubated with stavudine and zidovudine were enlarged and flattened (Figure 3B, bottom) – morphological changes typically associated with senescence [26].

Arrest of cell division was also indicated by the increased protein expression of p16$^{INK4}$ and p21$^{WAF-1}$, two cell-cycle checkpoint inhibitors that participate in the setup of the senescence program [34,35]. P16$^{INK4}$ and p21$^{WAF-1}$ were overexpressed by 250–400% in cells exposed to stavudine or zidovudine at passages 6–8 (Figure 4A). At the same passages, p16$^{INK4}$ and p21$^{WAF-1}$ protein expression was not different between control cells and cells exposed to the other NRTIs studied (Figure 4A and not shown).
Fibroblasts incubated with stavudine and zidovudine prematurely acquire a senescent phenotype. Strong cellular staining for X-gal at pH 4, indicating physiological lysosomal β-galactosidase activity, was detected in control and NRTI-treated fibroblasts. SA-β-galactosidase activity, assessed at pH 6, was absent in control cells up to passage 14, but present in cells incubated with stavudine or zidovudine (Figure 4B and data not shown). The number of X-gal-stained cells at pH 6 increased 40- to 60-fold, accounting for 33–85% of all cells. Little or no SA-β-galactosidase activity was detected in fibroblasts incubated with abacavir, didanosine, lamivudine and tenofovir up to passage 12 (Figure 4B and not shown). Microscopic examination (Figure 4B, bottom) showed that X-gal-stained fibroblasts at pH 6 incubated with stavudine or zidovudine displayed senescence-associated morphological changes.

Expression of senescence markers in adipose cells and HIV patients’ fat tissue
Mitochondrial function and oxidative stress in 3T3-F442A murine preadipocytes incubated with stavudine or zidovudine for 6 weeks (from passages 7–13; Figure 5A) were also evaluated. In preadipocytes exposed to stavudine, JC-1 aggregation and MTR fluorescence fell and rose, respectively, as a function of the duration of treatment, consistent with a reduction of the mitochondrial membrane potential and an increased mitochondrial mass. Oxidative stress was also observed in preadipocytes incubated for 1 week and more strikingly for 6 weeks with stavudine, as shown by two- and eight-fold increase in CM-H2DCFDA oxidation (Figure 5A). A 6-week incubation with stavudine or zidovudine, but not with lamivudine, also increased NBT reduction (by twofold in murine preadipocytes (Figure 5A).

Continuous exposure of 3T3-F442A preadipocytes to stavudine or zidovudine, but not lamivudine, was associated with a gradual decline in the PDL value (fourfold decrease at week 6 of treatment; Figure 5B, left). In keeping with the arrest of cell division, preadipocytes incubated with stavudine and zidovudine expressed increased levels of p16INK4 and p21WAF1 (Figure 5B, right). Accelerated senescence was also indicated by the increased pH 6/4 β-galactosidase activity ratio (0.073 ±0.009 and 0.597 ±0.198 in control and stavudine-treated cells, respectively, at weeks 5–6 of treatment; P=0.0287) and by the enlarged and flattened morphology of cells exposed to stavudine or zidovudine (not shown).

Subcutaneous adipose tissue samples from lipodystrophic HIV-infected patients on NRTI-based therapy containing stavudine or zidovudine without protease inhibitors had a markedly reduced COX2/COX4 expression ratio and increased levels of p16INK4 and p21WAF1, as compared with fat samples from healthy HIV-seronegative subjects (Figure 5C, left). Protein expression of COX4 and porin, adjusted to the β-actin level, was increased in fat samples from HIV-infected patients as compared with control (Figure 5C, right), suggesting that mitochondrial biogenesis could be enhanced in adipose tissue from NRTI-treated patients. These data indicate that adipose tissue in lipodystrophic HIV-infected patients treated with stavudine or zidovudine exhibited signs of mitochondrial dysfunction and senescence.
Discussion

HIV-infected patients tend to develop age-related complications such as diabetes, atherosclerosis, neurodegenerative disorders, osteopenia, sarcopenia and general loss of lean body mass earlier than the general population [40–43]. Moreover, the rate at which lipodystrophy worsens in HIV-infected patients increases with age [44,45], and middle-aged HIV-infected patients have an immune status [46] and frailty-related phenotype similar to that of older healthy subjects [47].

The toxicity of HIV antiretroviral treatments has been largely attributed to the mitochondrial toxicity of NRTIs [1,3–5,7,9,11]. Severe adverse events have been related to mitochondrial dysfunction, including lactic acidosis, hepatic steatosis, neuropathy, cardiomyopathy, pancreatitis [3–5,7] and lipoatrophy [6,10]. Mitochondrial toxicity in this setting has been more specifically attributed to the thymidine analogues stavudine and zidovudine. Several groups, including ours, have demonstrated that these two thymidine analogues induce mitochondrial alterations not only in cultured cells [12,14,15] but also in vivo, in the cells and fat tissue of HIV-infected patients [6,11,13,17,18,20]. A further argument for the mitochondrial toxicity of NRTIs is provided by the study of Mallon et al. [48] reporting that a 2-week treatment of healthy individuals with stavudine or zidovudine (in association with lamivudine) promoted adipose tissue mitochondrial dysfunctions.

Mitochondria dysfunction and mitochondrial oxidative stress are known key factors in several aging theories [29,30]. The free-radical theory of aging holds that aging and associated degenerative disorders can be attributed to deleterious effects of ROS. ROS are by-products of cellular metabolic pathways and function as crucial second messengers in a variety of intracellular signalling pathways [30]. They are primarily generated by the mitochondrial electron transport chain. Excessive intracellular generation of ROS on the one hand, and deficient anti-oxidant defence systems on the other, lead to a state of ‘oxidative stress’. Direct or indirect ROS involvement has been documented in numerous diseases and the mitochondrial network was identified as a prime target of oxidative damage [29,30].

In the present study we report that the thymidine analogues stavudine and zidovudine, but not the NRTIs abacavir, didanosine, lamivudine and tenofovir, induced mitochondrial dysfunction, increased mitochondrial proliferation and enhanced ROS production in cultured human fibroblasts. Moreover, 3T3-F442A preadipocytes incubated with stavudine or zidovudine for 6 weeks harboured markers of mitochondrial dysfunction, as did fat biopsy specimens from lipodystrophic HIV-infected patients on antiretroviral regimens containing these thymidine analogues. In cultured fibroblasts and preadipocytes, mitochondrial disorders and oxidative stress occurred early, beginning after only 1 week of treatment with stavudine or zidovudine, were maximal at week 3, and persisted throughout subsequent culture passages. This is in accordance with the rapid

Figure 3. NRTIs reduce proliferative and replicative capacity of human fibroblasts
deterioration of mitochondrial functions in adipose tissue from healthy subjects treated for 2 weeks with stavudine or zidovudine [48]. In our study, mitochondrial dysfunction was evidenced by three means: altered mitochondrial membrane potential, decreased expression of mtDNA-encoded mitochondrial proteins, and increased mitochondrial proliferation. NRTI-induced mitochondrial proliferation, observed by enhanced MTR staining and increased expression of two nDNA-encoded mitochondrial proteins (COX4 and porin), has also been reported in cultured adipocytes [15] and in patients’ fat samples [21,38].

Figure 4. NRTIs induce cell-cycle arrest and premature senescence in human fibroblasts

(A) Western blots of fibroblast lysates (passage 10) were revealed with antibodies against p16INK4a, p21WAF1 and β-actin, as indicated. Experiments were performed in triplicate. Representative blots are shown (left). The protein expression ratio of p16INK4a or p21WAF1/β-actin was determined by densitometric scanning and expressed as a percentage of control (mean ± SEM; right).

(B) Physiological lysosomal (pH 4) and senescence-associated-β-galactosidase (pH 6) activities were assessed by cellular X-gal blue staining. The ratio of pH 6/pH 4 positive blue cells was calculated after microscopic examination of 500 cells at the indicated passages (3–8) (top). Experiments were performed in triplicate. Representative conventional micrographs of X-gal-stained cells (passage 7) at pH 6 are shown (bottom). Scale bar represents 40 μm. Note the senescence-associated flattened and enlarged morphology of X-gal-stained cells incubated with stavudine and zidovudine.*P<0.05 as compared with control cells.
might be considered as a compensatory mechanism contributing to the relative preservation of mitochondrial functions. However, it can have deleterious consequences in genetic mitochondriopathies [49] suggesting, as in the present study, that newly formed mitochondria could be non-functional. Decreased mtDNA levels resulting from inhibition of DNA polymerase $\gamma$ is considered as a major marker of mitochondrial defects related to antiretroviral treatments [1,7,13]. However, dissociation between the mtDNA content and the expression of mtDNA-encoded mitochondrial proteins under NRTI exposure has been reported [19,48]. In the

Figure 5. Mitochondrial dysfunction and senescence markers in 3T3-F442A preadipocytes exposed to NRTIs (A,B) and in adipose tissue from HIV-seronegative controls and lipodystrophic HIV-infected patients under NRTI therapy (C)

(A) Mitochondrial dysfunction and ROS production were assessed at the indicated weeks of NRTI incubation, by JC-1 aggregation and Mitotracker Red (MTR) labelling and by the oxidation of CM-H$_2$DCFDA derivatives and reduction of nitroblue tetrazolium (NBT; see the Methods and legends of Figures 1 and 2). NBT reduction was assessed after 6 weeks of NRTI incubation. The experiments were performed in triplicate. (B) Preadipocytes were treated with the indicated NRTI. Mean PDL values $\pm$ SEM at the indicated passages are shown (left). Western blots of cell lysates were revealed with antibodies against p16$^{INK4A}$, p21$^{WAF1}$ and $\beta$-actin as indicated. Representative blots of preadipocytes exposed to NRTI (for 6 weeks) performed in triplicate are shown (right). (C) Lysates of subcutaneous fat tissue from control HIV-seronegative subjects or lipodystrophic HIV-infected patients under stavudine or zidovudine therapy were submitted to western blot with the indicated antibodies. Representative blots (performed in triplicate) are shown (left). COX2/COX4, COX4/$\beta$-actin and porin/$\beta$-actin protein ratios were determined by scanning densitometry and expressed as a percentage of control (mean $\pm$SEM) (right). *$P<0.05$ as compared with control cells.
present study inconclusive preliminary data have been obtained on the effect of a 4-week incubation of fibroblasts with stavudine, zidovudine or lamivudine on mtDNA level, whereas during the same period the thymidine analogues markedly altered mitochondrial membrane potential, COX2, COX4 and porin protein expression, mitochondrial mass and ROS production, consistent with their mitochondrial toxicity. It is possible that the mtDNA level would decrease at later culture passages in fibroblasts, a time at which ROS level and toxicity were markedly enhanced. We previously reported [15] that 3T3-F442A adipocytes incubated for 4 weeks with stavudine or zidovudine had a severe decrease in mtDNA, as compared with untreated adipocytes, suggesting that the severity of mtDNA alterations could be tissue-specific.

We show here that mitochondrial toxicity of stavudine and zidovudine is associated with a rapid and sustained increase of ROS production in human fibroblasts and murine preadipocytes. Interestingly, short-term incubation of human adipocytes or macrophages with these NRTIs also induced oxidative stress [50]. Increased oxidative stress and abnormal antioxidant defenses have also been demonstrated in HIV-infected patients, including patients treated with NRTIs [24,25,51].

Stavudine and zidovudine triggered the senescence program prematurely in cultured human skin fibroblasts and 3T3-F442A preadipocytes. Indeed, the cells continuously exposed to stavudine or zidovudine showed a gradual slowing of cell proliferation and division, acquired the morphology of senescent cells, and expressed SA-β-galactosidase activity. At later passages they expressed the cell-cycle checkpoint inhibitors p16INK4a and p21WAF1, a finding consistent with cell cycle arrest. In contrast, long-term incubation with abacavir, lamivudine and tenofovir did not alter mitochondrial function or the ROS level and did not trigger premature senescence, in accordance with their weak mitochondrial toxicity [52,53]. It is noteworthy in this respect that these NRTIs carry a lower risk of lipodystrophy than stavudine or zidovudine [10].

Interestingly, the effects of the thymidine analogues on mitochondrial markers and oxidative stress in human fibroblasts were maximal after 3 weeks of treatment, whereas senescence markers were maximally altered after 13 weeks. A similar lag time between mitochondrial toxicity and senescence entry was also observed in 3T3-F442A preadipocytes treated with stavudine. This sequence of events points to a role of mitochondrial oxidative stress in NRTI-induced premature senescence, although we could not produce definitive experimental evidence for a direct relationship. Experiments using antioxidants might help to elucidate the role of ROS in NRTI-induced premature senescence. We could not exclude that cytosolic ROS originating from the NADPH oxidase pathway could contribute to senescence triggering and, in a vicious circle, further increase mitochondrial alterations.

Although an association between NRTI-induced mitochondrial alterations, ROS hyperproduction and senescence has been shown in vitro, in proliferating cells (fibroblasts and preadipocytes), it is not possible to extrapolate to other tissues and especially...
Antiretrovirals induce premature senescence in vitro

non-proliferative cells. In the present setting, the effect of the drugs could relate not only to the increased number of replicative rounds, but also to the length of the exposure. It would be interesting to assess whether older fibroblasts, exposed to the drugs at later passages, would be more sensitive to the deleterious action of stavudine or zidovudine. It also remains to be investigated whether the setup of the senescence program triggered by the thymidine analogues could be blocked or reversed by arresting or substituting the drugs.

The pathophysiological relevance of these findings is supported by the detection of markers of mitochondrial dysfunction and senescence in fat tissue from lipodystrophic HIV-infected patients on stavudine- or zidovudine-based antiretroviral regimens, although data on the mitochondria and senescence status of untreated HIV-infected patients are lacking. Otherwise, the mechanisms whereby HIV-infected patients develop several age-related comorbidities are obviously multifactorial, resulting from therapy with aggressive NRTIs, but also from HIV infection or co-treatment with other antiretrovirals. Accordingly, we recently reported that some protease inhibitors can trigger premature senescence via a mitochondrial oxidative stress, in vitro, in cultured fibroblasts, and in vivo at the fat tissue level of HIV-infected patients [37]. Protease inhibitor effects were shown to result from the cellular stress linked to farnesylated prelamin A, a nuclear precursor of lamin A, the accumulation of which leads to severe genetically determined premature ageing syndromes [54]. Although prelamin A accumulation was not observed in NRTI-treated cells (data not shown), protease inhibitors and NRTIs may work in synergy to trigger a mitochondrial oxidative stress and aggravate age-related diseases in HIV-infected patients.

Interestingly, premature ageing syndromes are known to be associated with lipodystrophy [54] and the prevalence and severity of the lipodystrophy phenotype in HIV-infected patients under antiretrovirals both increased with age [44,45]. This suggests that premature adipose tissue aging could be one mechanism whereby antiretrovirals induce lipodystrophy.

Taken together these results show the contribution of mitochondrial dysfunction and oxidative stress to cellular premature senescence induced by antiretroviral thymidine analogues. Validation of these results with longitudinal cohorts of HIV-infected patients is required to confirm the link between the toxicity of antiretroviral treatment and aging-related comorbidities.

Acknowledgements

We thank P Levan for providing the adipose tissue samples and V Jan for preparing the fat samples extracts. This work was supported by grants from INSERM, Agence Nationale pour la Recherche sur le SIDA, Sidaction and from European Union's FP6 Life Science, Genomics and Biotechnology for Health (LSHM-CT-2005-018690).

Disclosure statement

MC received a travel grant and honoraria for conference attendance from Glaxo Smith Kline. CV received a travel grant from Gilead and honoraria for conference attendance from Bristol Myers Squibb. JC received travel grants and/or honoraria for conferences from Glaxo Smith Kline, Bristol Myers Squibb, Vertex, Abbott, Roche and Sanofi-Aventis.

References


